BioSpace News Archive

Business

BioTelemetry Reports Third Quarter 2017 Financial Results

Recognized highest quarterly revenue in Company’s history of $81.0 million, a 52.7% increase over the prior year driven by the acquisition of LifeWatch AG.

November 8, 2017
·
26 min read
Business

Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update

Prothena reported a net loss of $52.4 million and $105.5 million for the third quarter and first nine months of 2017.

November 8, 2017
·
11 min read
Business

OpGen Reports 2017 Third Quarter Financial Results and Provides Business Update

Affirms plans to release Acuitas AMR Gene Panel in the first quarter of 2018.

November 8, 2017
·
11 min read
Business

HTG Molecular Diagnostics Reports 2017 Third Quarter Earnings

Revenue increased 307% and 87%, respectively, compared to the three and nine month periods in the prior year.

November 8, 2017
·
8 min read
Business

Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results

Total revenues of $190.2 Million is up 7 percent.

November 8, 2017
·
20 min read
Business

Novavax Reports Third Quarter 2017 Financial Results

Novavax reported a net loss of $44.6 million, or $0.15 per share, for the third quarter of 2017, compared to a net loss of $66.3 million, or $0.24 per share, for the third quarter of 2016.

November 8, 2017
·
7 min read
Drug Development

Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana

The Podium presentation was given by Dr. Ivan Grunberger MD FACS, Professor of Clinical Urology, Weill Cornell Medical College and Chief of Urology, NYP Brooklyn Methodist Hospital.

November 8, 2017
·
4 min read
Business

Moleculin Appoints Dr. Sandra Silberman as CMO - New Products

Moleculin Biotech announced the appointment of Dr. Sandra Silberman as CMO in charge of New Products.

November 8, 2017
·
4 min read
Business

STAAR Surgical Reports Third Quarter 2017 Results

Quarterly net sales of $23.5 million up 17% from the prior year quarter.

November 8, 2017
·
34 min read
Business

Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Research and development expenses for the three months ended September 30, 2017 were $3.5 million compared to $2.1 million for the same period in 2016.

November 8, 2017
·
19 min read